Compare ESOA & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESOA | PLYX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.3M | 271.8M |
| IPO Year | 2006 | N/A |
| Metric | ESOA | PLYX |
|---|---|---|
| Price | $16.70 | $2.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $21.00 | $10.00 |
| AVG Volume (30 Days) | 132.0K | ★ 336.3K |
| Earning Date | 05-11-2026 | 05-22-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $122,465,826.00 | N/A |
| Revenue This Year | $9.22 | N/A |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | $96.47 | ★ N/A |
| Revenue Growth | ★ 2.74 | N/A |
| 52 Week Low | $7.84 | $2.01 |
| 52 Week High | $19.94 | $9.18 |
| Indicator | ESOA | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 38.28 |
| Support Level | $16.62 | $2.07 |
| Resistance Level | $19.94 | $3.41 |
| Average True Range (ATR) | 0.88 | 0.45 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 54.55 | 20.62 |
Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is predominantly engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical, and automotive industries and does incidental work such as water and sewer projects. Energy Service's other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services, and other services related to pipeline construction.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.